​

Cyclerion Therapeutics (CYCN) Revenue & Revenue Breakdown

OverviewOwnershipFinancialsChart

Cyclerion Therapeutics Revenue Highlights

Latest Revenue (Y)

$2.00M

Latest Revenue (Q)

$194.00K

Main Segment (Y)

License Agreement

Cyclerion Therapeutics Revenue by Period

Cyclerion Therapeutics Revenue by Year

DateRevenueChange
2024-12-31$2.00M100.00%
2023-12-31--100.00%
2022-12-31$297.00K-91.05%
2021-12-31$3.32M44.60%
2020-12-31$2.30M-49.06%
2019-12-31$4.51M100.00%
2018-12-31-100.00%
2017-12-31-100.00%
2016-12-31--

Cyclerion Therapeutics generated $2.00M in revenue during NA 2024, up 100.00% compared to the previous quarter, and up 44.38% compared to the same period a year ago.

Cyclerion Therapeutics Revenue by Quarter

DateRevenueChange
2024-09-30$194.00K100.00%
2024-06-30-100.00%
2024-03-31-100.00%
2023-12-31-100.00%
2023-09-30-100.00%
2023-06-30-100.00%
2023-03-31--100.00%
2022-12-31$1.63M100.00%
2022-09-30--100.00%
2022-06-30$72.00K-68.00%
2022-03-31$225.00K23.63%
2021-12-31$182.00K136.36%
2021-09-30$77.00K-97.43%
2021-06-30$3.00M4738.71%
2021-03-31$62.00K-53.38%
2020-12-31$133.00K-66.75%
2020-09-30$400.00K-46.60%
2020-06-30$749.00K-26.13%
2020-03-31$1.01M-31.53%
2019-12-31$1.48M5.94%
2019-09-30$1.40M-14.13%
2019-06-30$1.63M100.00%
2019-03-31-100.00%
2018-12-31-100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31--

Cyclerion Therapeutics generated $194.00K in revenue during Q3 2024, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Cyclerion Therapeutics Revenue Breakdown

Cyclerion Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24
License Agreement$1.75M
License$250.00K

Cyclerion Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: License Agreement (87.50%), and License (12.50%).

Cyclerion Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
LIPOLipella Pharmaceuticals$536.36M$80.38M
FENCFennec Pharmaceuticals$47.54M$6.97M
KRONKronos Bio$9.85M$2.37M
XFORX4 Pharmaceuticals$2.56M$560.00K
CYCNCyclerion Therapeutics$2.00M$194.00K
ADXNAddex Therapeutics$1.61M$235.00K
SONNSonnet BioTherapeutics$147.81K$1.00M
CDIOCardio Diagnostics$2.02K$6.58K
ZVSAZyVersa Therapeutics--
FBRXForte Biosciences--
ACHLAchilles Therapeutics--
KZRKezar Life Sciences--
ERASErasca--
SNTISenti Biosciences--
LRMRLarimar Therapeutics--
MNPRMonopar Therapeutics--

CYCN Revenue FAQ

What is Cyclerion Therapeutics’s yearly revenue?

Cyclerion Therapeutics's yearly revenue for 2024 was $2M, representing an increase of 100.00% compared to 2023. The company's yearly revenue for 2023 was $0, representing a decrease of -100.00% compared to 2022. CYCN's yearly revenue for 2022 was $297K, representing a decrease of -91.05% compared to 2021.

What is Cyclerion Therapeutics’s quarterly revenue?

Cyclerion Therapeutics's quarterly revenue for Q3 2024 was $194K, a 100.00% increase from the previous quarter (Q2 2024), and a 0% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). CYCN's quarterly revenue for Q1 2024 was $0, a 100.00% increase from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023).

What is Cyclerion Therapeutics’s revenue growth rate?

Cyclerion Therapeutics's revenue growth rate for the last 3 years (2022-2024) was 573.40%, and for the last 5 years (2020-2024) was -12.89%.

What are Cyclerion Therapeutics’s revenue streams?

Cyclerion Therapeutics's revenue streams in c 24 are License Agreement, and License. License Agreement generated $1.75M in revenue, accounting 87.50% of the company's total revenue License generated $250K in revenue, accounting 12.50% of the company's total revenue

What is Cyclerion Therapeutics’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Cyclerion Therapeutics was License Agreement. This segment made a revenue of $1.75M, representing 87.50% of the company's total revenue.